News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

PathAI Launches New Pathologist-Centric Features on AISight to Enable Efficient Case Review through Intelligent Case Prioritization and Real-Time Multi-Institutional Collaboration

PathAI

PathAI, Inc., a leading AI-powered precision pathology company, today announced the availability of two new features on the AISight digital pathology image management system – an Intelligent Caselist and AISight Live. AISight is a cloud-based platform that serves as a central hub for case management, image management, and best-in-class artificial intelligence to enable efficient end-to-end digital pathology workflows. The latest AISight enhancements represent PathAI’s ongoing commitment to empowering pathologists with cutting-edge solutions that improve pathology assessment and laboratory operations and lay the groundwork for broader implementation of AI tools in pathology. AISight Live includes a suite of features to optimize real-time collaboration for a variety of use cases, and its Sync view allows users to follow one another as they navigate the slide – providing real-time case review and interaction with users remotely. An AISight Live Participants list allows users to invite other pathologists for ‘over the shoulder’ and multi-headed scope review/consults, live tumor boards, educational seminars and training, and anonymized viewing to mask PHI if necessary. “The AISight Live collaboration suite marks a significant leap in optimizing remote interactions amongst pathologists,” says Eric Walk, PathAI Chief Medical Officer. “This feature holds immense promise in enhancing collaborative efforts, fostering knowledge exchange, driving resident education, and ultimately improving collaboration through efficient and dynamic pathology workflows.” The Intelligent Caselist features an information-rich data table and three filterable charts, providing pathologists and lab personnel a more streamlined view of their case workload, and allowing for embedded AI to assist in case prioritization. “We’re confident that the AISight Live and the Intelligent Caselist features will simplify pathology workflows and speed up the more tedious tasks – such as case prioritization,” said Pete Romanowich, PathAI Vice President of Program Management and Platform Product. “These features will streamline and optimize pathologist workflows, providing pathologists more time to operate at the top of their license and focus their attention where it matters most.” The AISight platform was created with input from hundreds of pathologists from dozens of institutions, and its launch, and enhancements, underpins all the work PathAI does to support pathologists, biopharma partners and those in the academic research community. AISight Live and the Intelligent Caselist are another critical step in PathAI’s quest to improve patient outcomes with AI-powered pathology. PathAI launched AISight as an IMS in September 2023. Many leading anatomic pathology laboratories ranging from reference laboratories, to independent laboratories and academic medical centers are now using AISight. To learn more about AISight, PathAI’s Image Management System, join our next webinar on February 29, for a live demo of the latest AISight enhancements and an overview of our 2024 product roadmap. AISight is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

February 27, 2024 10:00 AM Eastern Standard Time

Article thumbnail News Release

Vaping: Know the Truth: Youth Vaping Prevention & Resources to Quit

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/LXqBkJ5imDA E-cigarette use remains a public health threat among youth and young adults with more than 2.1 million middle and high schoolers currently using e-cigarettes, according to the 2023 National Youth Tobacco Survey. Nearly one in four students surveyed use e-cigarettes vape every day or nearly daily, underscoring the highly addictive nature of nicotine, which is harmful to developing brains. It doesn’t stop there. A recent study revealed that teen cannabis use has increased by 245% over the past two decades and approximately 15% of high school seniors who have ever used cannabis become daily or near daily users. On February 5th, a media tour was conducted featuring Amy Taylor, Chief of Community Engagement for Truth Initiative and teachers who use the Vaping: Know the truth curriculum. Vaping: Know the truth is a free, comprehensive digital curriculum designed to empower students by giving them the facts about the health dangers of e-cigarettes and providing resources for youth who vape to quit and made available to schools by leading social impact education innovator, EVERFI. Truth Initiative also recently added two new lessons to the Vaping: Know the truth curriculum to equip students with knowledge about the health effects of vaping cannabis. The new cannabis-focused lessons equip students with knowledge regarding cannabis in vaping products, including short- and long-term health effects, consequences, and risks. Since its launch, more than one million students across the country have actively engaged with the curriculum. It is a self-led interactive online course with peer-to-peer instruction. It was developed as part of Truth Initiative’s proven-effective and nationally recognized truth youth public education campaign. In addition to encouraging students to live vape-free lives, Vaping: Know the truth offers resources to help young people who are currently using e-cigarettes to quit through truth’s first-of-its-kind text message youth quit vaping program This is Quitting, which is already helping more than 700,000 youth and young adults on their journeys to quit. The curriculum also has suggested resources available for young people looking to quit cannabis. For more information, visit TRUTHINITIATIVE.ORG/VAPING-CURRICULUM Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 26, 2024 12:25 PM Eastern Standard Time

Video
Article thumbnail News Release

Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours

Clearmind Medicine Inc

Clearmind Medicine Inc CEO Dr. Adi Zuloff-Shani joined Steve Darling from Proactive to announce a significant milestone for the company: the granting of divisional patent approval by the China National Intellectual Property Administration (CNIPA). This latest patent approval solidifies Clearmind's patent protection for its flagship molecule and further establishes its extensive intellectual property (IP) protection in the psychedelic space. Clearmind's IP portfolio now encompasses fifteen utility patent families, including patents and applications with method of use and composition of matter claims. This includes 24 pending patent applications and 27 granted patents in key jurisdictions such as the US, Europe, China, and India. The company's robust IP portfolio positions it as a leader in the development of innovative treatments in the psychedelic field. Dr. Zuloff-Shani provided insights into Clearmind's flagship molecule, MEAI, which has shown promise in reducing the desire to consume alcoholic beverages while inducing a slight euphoric, alcohol-like experience. This treatment targets Alcohol Use Disorder, a prevalent condition characterized by an individual's inability to control their alcohol consumption despite negative consequences. MEAI also holds potential in addressing binge drinking, offering hope for individuals struggling with this harmful addiction. Clearmind plans to commence clinical trials for alcohol use disorder, expand their IP portfolio, and explore M E's potential in treating obesity. With collaborations with esteemed institutions like Johns Hopkins and Yale, Clearmind aims to revolutionize addiction treatment and offer innovative solutions to societal challenges. Stay tuned for their exciting developments in 2024. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 26, 2024 10:37 AM Eastern Standard Time

Video
Article thumbnail News Release

Cardiff Lexington CEO Alex Cunningham Discusses Healthcare Growth Strategy

Cardiff Lexington Corporation

Cardiff Lexington CEO Alex Cunningham joined Steve Darling from Proactive to discuss the company's transformation into an acquisition-oriented healthcare firm with a focus on orthopedic surgery centers. Cardiff Lexington's revenue primarily stems from bodily injury and general liability insurance coverages, providing insulation from pricing downsides associated with Medicare and Medicaid. Cunningham emphasized the unique accounts receivable structure of the company, along with its focus on uninsured coverages, which contribute to maintaining high collectability rates. He also highlighted the increasing demand for orthopedic services driven by an aging population, positioning Cardiff Lexington for growth in this market. The company's recent financial performance showed significant increases in revenue, net earnings, and assets, reflecting its strategic focus and operational efficiency. Looking ahead to 2024, Cardiff Lexington plans to continue its expansion through acquisitions, market expansion initiatives, and strategic partnerships. Furthermore, Cunningham mentioned the company's plans to release its 10k in early March and pursue an uplift to a major exchange in 2024, with a clear focus on enhancing shareholder value and achieving strategic growth objectives. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 26, 2024 10:32 AM Eastern Standard Time

Video
Article thumbnail News Release

IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025

IQ-AI Ltd

Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Limited sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring glioblastoma patients. Connelly explained that glioblastoma, the most common malignant brain tumour, significantly impacts brain function, highlighting the importance of clinical trials to improve patient quality of life. The trial, opened nearly two years ago, investigates gallium maltolate, an oral medication showing promise in preclinical studies and animal models for efficacy against tumour cells. This phase focuses on drug tolerance, with patients reporting ease of use compared to traditional treatments and the ability to maintain normal daily activities. An expanded access programme (EAP), also known as compassionate use, has been launched by IA-AI subsidiary Imaging Biometric to allow wider access to gallium maltolate across the country, benefiting patients unable to travel to the Medical College of Wisconsin. The EAP, approved by the FDA, aims to collect additional safety and toxicity data, contributing to the trial's findings and supporting the progression towards a phase two clinical trial. The next milestone, by the end of 2024, involves concluding the phase one trial, determining the maximum tolerated dose, and preparing for the phase two trial slated for 2025, focusing on safety and beginning to evaluate efficacy. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

February 26, 2024 09:51 AM Eastern Standard Time

Video
Article thumbnail News Release

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Benzinga

By Faith Ashmore, Benzinga Researchers, scientists and practitioners in the past few decades have begun to look at healthcare from a more holistic perspective, often challenging traditional medicine. The question on the minds of many is how to integrate holistic medicine into American healthcare – at scale. One company, Better Therapeutics (NASDAQ: BTTX) is doing just that and trying to revolutionize how healthcare providers treat diseases like diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Better Therapeutics is taking a comprehensive approach to address the root causes of these diseases through the development of a novel form of cognitive behavioral therapy (CBT) that it delivers digitally – enabling near-infinite scalability. Its novel form of CBT has been proven to work for the treatment of type 2 diabetes, helping patients make sustainable lifestyle changes by exploring how their thoughts and beliefs impact their actions – and ultimately their health. However, like much of holistic medicine, without proper FDA authorization and established reimbursement pathways this type of treatment is not accessible or affordable for the millions of patients who could benefit from it. Better Therapeutics has officially secured Breakthrough Device Designation for its groundbreaking CBT platform, intended to treat MASH. MASLD affects roughly 25%-30% of adults around the world, with an even higher prevalence of 75% among individuals with type 2 diabetes and up to 90% among those with advanced obesity. MASH, a more advanced form of the disease, affects approximately 20% of the 25% of American adults who have MASLD and is currently one of the leading indications for liver transplants. Despite the growing rates of MASLD and MASH, there are currently no FDA-approved drugs or devices for treatment. Milestones Hit In 2023 This news comes after Better Therapeutics’ LivVita study's results were published in the peer-reviewed journal Gastro Hep Advances, validating the CBT-based approach. The study successfully achieved its primary endpoint of reducing liver fat in just 90 days, along with significant improvements in liver health through key secondary endpoints, without any device-related adverse events. The study is the first of its kind to demonstrate improvements in various markers, such as FibroScan CAP score, MRI-PDFF, weight, ALT and FastTM score. These results suggest that the treatment has significant therapeutic potential for a larger patient population. Additionally, the study reported no device-related adverse events, even in patients with multiple comorbidities and background pharmacotherapy use. In 2023, Better Therapeutics also received FDA Authorization for its first product, AspyreRx TM, to treat adults with type 2 diabetes. AspyreRx underwent rigorous clinical testing – including a large randomized controlled trial – to demonstrate safety and efficacy. Better Therapeutics reports that the trial showed statistically significant and clinically meaningful decreases in blood sugar when compared to a control group receiving the current standard of care. Specifically, over 50% of patients achieved a clinically meaningful response, with those patients experiencing an average drop of 1.3% in blood sugar as measured by HbA1c; this is similar to what is seen in other modern drug trials. In addition, patients who used AspyreRx were also generally healthier: exploratory data revealed a range of cardiometabolic improvements, including blood pressure, body weight, quality of life, mood, safety and lower medication utilization compared to the control group. In September, the company completed enrollment in a real-world evidence program evaluating the long-term effectiveness of AspyreRx in type 2 diabetes. Given the escalating prevalence, soaring costs and growing burden of cardiometabolic diseases, there is a crucial need to revolutionize how we approach their treatment. Better Therapeutics’ revolutionary approach could open doors for physicians and patients who are looking for more effective methods of treatment. While companies like Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have seen success with diabetes medication, Better Therapeutics’ transformative solution may have the potential to change the trajectory of the disease. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 26, 2024 08:15 AM Eastern Standard Time

Article thumbnail News Release

Immunic reports successful 2023 and prepares for key 2025 milestones

Immunic Inc

Immunic Inc CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion following what he described as a successful 2023. Outlining the company's achievements, Dr Vitt noted the company strengthened its balance sheet by raising up to $240 million. The first tranche of the three tranche private placement is expected to extend the company's cash runway into the third quarter of 2025, beyond important clinical readouts for its Phase 2 study in progressive multiple sclerosis (MS), known as the CALLIPER study, with results anticipated in April 2025. Clinically, Immunic achieved positive results across its portfolio, including its Vidofludimus calcium and IMU-856. Dr Vitt said vidofludimus calcium showed promising phase 2 interim results in 2023, including a significant reduction in NfL biomarkers in patients with progressive MS, indicating its potential as a unique treatment option. IMU-856, targeting gastrointestinal disorders, demonstrated effectiveness in improving gut function in celiac disease patients, with results published in spring 2023. Looking ahead to 2024, he said the focus is on preparing for the CALLIPER study readout in April 2025 and exploring further studies for IMU-856 in additional indications. The company continues discussions with potential pharmaceutical partners for its programs. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 22, 2024 10:59 AM Eastern Standard Time

Video
Article thumbnail News Release

How AI is Transforming Healthcare and Saving Lives

MarketJar

Artificial intelligence (AI) is completely transforming everyday life. From entertainment to transportation, AI is being used to make our lives easier and more efficient. But none of those applications compare to its life-altering impact on healthcare. AI is an absolute game-changer for the healthcare industry, helping save countless lives through precision medicine, robotics-assisted surgery, and connected devices. It’s also becoming increasingly valuable in identifying complex illnesses at an earlier stage. AI-powered diagnostics leverage machine learning algorithms to analyze diverse data like medical records, genetics, and scans for early disease detection by identifying subtle patterns and anomalies often missed by human doctors. AI's rapid and precise data processing highlights subtle health changes, potentially revealing underlying diseases or risk factors. For instance, AI can review mammograms to detect early-stage breast cancer not visible to the naked eye. Over the next five years, the AI healthcare market is expected to grow at a compound annual growth rate (CAGR) of 48.1%, jumping from $20.9 billion in 2024 to $148.4 billion by 2029. As Big Pharma companies roll out bold AI plans for the coming years, one company is developing and acquiring technology and clinical expertise to create an AI-driven medical powerhouse that supports doctors, curbs rising healthcare costs and improves patient outcomes. HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF is a physician-led healthcare technology company that is focused on AI and data science for preventive care. In a whirlwind four months since its debut on the Toronto Stock Exchange, HEALWELL AI has rapidly gained financial strength, securing approximately $29.5 million and firmly establishing itself as a savvy capital allocator in the AI healthcare space after completing two transformative acquisitions. AI Accelerated Preventive Healthcare Late last year, HEALWELL AI secured a majority stake in Pentavere, a globally recognized, award-winning AI healthcare company specializing in identifying eligible patients for approved treatments. With a successful history of real-world evidence studies and key hospital network collaborations, Pentavere's DARWEN™ AI technology carries validation from global pharmaceutical leaders and has garnered recognition in renowned publications worldwide. The Pentavere deal will provide several key benefits including significant top-line revenue growth through Pentavere's established client base and successful commercialization of real-world evidence studies, strong partnerships with major hospital networks in Canada and the US to expand HEALWELL 's market reach and grant access to new patient demographics, and a team of AI engineers with invaluable to fortify the company's technological capabilities. Following the completion of the acquisition, Pentavere introduced DERMAID, an innovative Real-World Evidence (RWE) solution tailored for Dermatologists and life sciences firms. Leveraging the DARWEN™ AI platform, DERMAID extracts actionable clinical insights to enhance patient care decisions in dermatology. The product has quickly gained traction in the market and has already engaged in commercial activities with multiple leading pharmaceutical companies. HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF also just finalized the acquisition of Intrahealth Systems, a multinational SaaS-based EHR (Electronic Health Record) provider supporting 15,000 clinicians that care for millions of patients in its global network across Canada, Australia and New Zealand. In 2024, Intrahealth is projected to generate over $12 million in revenue, showing double-digit organic growth. Historically, the company has maintained strong financial performance with over 80% gross margins, positive EBITDA, and positive cash flow. Moreover, more than 80% of its revenue comes from recurring sources, which are highly profitable. HEALWELL 's strategic vision involves a deep integration of its cutting-edge AI tools with Intrahealth's platform to pioneer a next-generation AI-powered EHR, aligning with Value-Based Care (VBC) trends and empowering healthcare providers to achieve better health outcomes at reduced costs. HEALWELL has solidified its support structure through a strategic partnership with WELL Health Technologies, the largest clinic group in Canada. WELL Health has invested in each of HEALWELL 's financings, making them the largest shareholder and helping position HEALWELL as a leader in AI-enabled healthcare technology in North America. The alliance between WELL Health and HEALWELL led to the launch of the WELL AI Decision Support service for healthcare providers. This new service is designed to be highly adaptable and is expected to grow over time. Initially, WELL AI Decision Support will enable healthcare providers to accurately identify over 150 complex or rare diseases that are often overlooked by traditional methods. HEALWELL AI is actively pursuing a robust pipeline of potential acquisitions, having evaluated over 100 opportunities to date. Heading into 2024, the company is in talks with various parties to identify new investment and acquisition targets. Their M&A approach focuses on companies with solid revenue, positive EBITDA, and promising growth prospects. Click on this link or check out the investor presentation to learn more about HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF). Disclosure: 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies outlined in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of Healwell AI Inc. Market Jar Media Inc. was not paid for the production and publishing of this article by Healwell AI Inc. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 5) An officer of Market Jar Media Inc. holds 5,483 shares that were purchased at a price of C$0.80 per share on December 20th, 2023. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Healwell AI Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Healwell AI Inc.’s industry; (b) market opportunity; (c) Healwell AI Inc.’s business plans and strategies; (d) services that Healwell AI Inc. intends to offer; (e) Healwell AI Inc.’s milestone projections and targets; (f) Healwell AI Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Healwell AI Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Healwell AI Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Healwell AI Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Healwell AI Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e) Healwell AI Inc.’s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Healwell AI Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Healwell AI Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Healwell AI Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Healwell AI Inc.’s business operations (e) Healwell AI Inc. may be unable to implement its growth strategy; and (f) increased competition.Except as required by law, Healwell AI Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Healwell AI Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Healwell AI Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Healwell AI Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Healwell AI Inc. or such entities and are not necessarily indicative of future performance of Healwell AI Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

February 21, 2024 08:30 AM Eastern Standard Time

Image
Article thumbnail News Release

Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments

Benzinga

Oncotelic Therapeutics (OTCQB: OTLC), a therapeutics company with a focus on cancer and viral infection treatments, recently published a foundational discovery in pediatric brainstem tumors. The study showed that levels of two specific molecules – Transforming Growth Factor Beta 2 (TGF-B2) and Interferon Gamma Receptor 2 (IFNGR2) – in the tumor environment of children with diffuse midline gliomas (DMG) can significantly impact their overall survival. IFNGR2 is an important part of the body's immune system and helps fight against cancer. High expression of TGF-B2 in patients with low IFNGR2 reduced median survival from 13 months to only 7 months. Therefore, suppressing TGF-B2 with a drug called OT-101 could enhance the immune system's ability to fight tumor growth and improve survival. This finding could have implications for new cancer immunotherapy treatments. "In light of our foundational discovery that elevated levels of TGF-B2 worsen mortality in various cancers, including Diffuse Midline Glioma (DMG), we have further elucidated the underlying mechanisms, particularly focusing on the impact of TGF-B2 on interferon signaling. We hope that sharing these findings from our research team will contribute to the eradication of cancer," shared Dr. Vuong Trieu, CEO and Chairman of Oncotelic. Oncotelic has been involved in developing many cancer and viral infection treatments, including for COVID-19. The company currently has five drug candidates in its pipeline and recently unveiled a state-of-the-art GMP Manufacturing Plant through its joint venture- Sapu Biosciences LLC. The facility is situated in San Diego’s biotechnology hub. This plant will help with the expansion of the drug OT-101, among others. OT-101, also known as Trabedersen, is being developed for the treatment of various types of cancer, including brain cancer in adults and a specific type of childhood brain cancer called diffuse intrinsic pontine glioma (DIPG). OT-101 is an antisense oligodeoxynucleotide that targets TGF-B2, which is commonly found in cancer cells. As Oncotelic’s study found, cancer cells often overexpress TGF-B2, which dampens the body's immune response to the cancer. The company has received pediatric designation from the FDA specifically for the treatment of DIPG in children. This drug has shown promising results in early clinical trials for pancreatic cancer, melanoma and glioblastoma, demonstrating both efficacy and safety. Oncotelic’s partnership with Sapu Biosciences has a common goal of being a global leader in the research, development and commercialization of innovative therapies focusing on conditions with extreme unmet medical needs, especially age-related diseases. This is evident in the drug pipeline with its focus on cancers like DIPG, which is highly aggressive and difficult to treat. Approximately 300 children in the U.S. are diagnosed with DIPG each year. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 21, 2024 08:20 AM Eastern Standard Time

1 ... 5354555657 ... 301